Nodular lymphocyte predominance Hodgkin's disease and its differential diagnosis;La maladie de Hodgkin nodulaire à prédominance lymphocytaire et ses diagnostics différentiels

Annales de Pathologie

Volumn 24, Issue 2, 2004, Pages 136-148

  Carbonnelle, Amélie ^a   Delarue, Richard ^b   Canioni, Danielle ^a   Brousse, Nicole ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

Lymphocyte rich classic Hodgkin's disease; Nodular lymphocyte predominance Hodgkin's disease; Nodular paragranuloma; T cell or histiocyte rich large B cell lymphoma

Indexed keywords

ANTIGEN; CD15 ANTIGEN; CD20 ANTIGEN; CD3 ANTIGEN; CD30 ANTIGEN; EPITHELIAL MEMBRANE ANTIGEN; INTERFERON REGULATORY FACTOR 4; PROTEIN BCL 6; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR BOB1; TRANSCRIPTION FACTOR BSAP; TRANSCRIPTION FACTOR PU 1; UNCLASSIFIED DRUG;

ARTICLE; B CELL LYMPHOMA; B LYMPHOCYTE; CANCER CLASSIFICATION; CELL PROLIFERATION; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; EPSTEIN BARR VIRUS; GERMINAL CENTER; HISTIOCYTE; HODGKIN DISEASE; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPHOCYTE RICH CLASSIC HODGKIN DISEASE; NODULAR LYMPHOCYTE PREDOMINANCE HODGKIN DISEASE; NODULAR PARAGRANULOMA; NOMENCLATURE; PATHOLOGY; PROGNOSIS; REED STERNBERG CELL; T CELL OR HISTIOCYTE RICH LARGE B CELL LYMPHOMA; T LYMPHOCYTE; TUMOR CELL;

EID: 3843093721     PISSN: 02426498     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0242-6498(04)93937-5     Document Type: Short Survey

References (67)

1. Lukes RJ, Craver LF, Hall TC, Rappaport H, Ruben P. Report of the nomenclature committee. Cancer Res 1966; 26: 1311.
2. Jaffe ES, Harris NL, Stein H, Vardiman JW. World Health Organization Classification of tumours. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press, 2001.
3. Pileri SA, Ascani S, Leoncini L, Sabattini E, Zinzani PL, Piccaluga PP et al. Hodgkin's lymphoma: the pathologist's viewpoint. J Clin Pathol 2002; 55: 162-76.
4. Jackson H. Classification and prognosis of Hodgkin's disease and allied disorders. Surg Gynecol Obstet 1937; 64: 465.
5. Bräuninger A, Kuppers R, Strickler JG, Wacker HH, Rajewsky K, Hansmann ML. Hodgkin and Reed-Sternberg cells in lymphocyte predominant Hodgkin disease represent clonal populations of germinal center-derived tumor B cells. Proc Natl Acad Sci USA 1997; 94: 9337-42.
6. Ramsay AD, Smith WJ, Isaacson PG. T-cell-rich B-cell lymphoma. Am J Surg Pathol 1988; 12: 433-43.
7. Achten R, Verhoef G, Vanuytsel L, DeWolf-Peeters C. Histiocyte-rich, T-cell-rich B-cell lymphoma: a distinct diffuse large B-cell lymphoma subtype showing characteristic morphologic and immunophenotypic features. Histopathology 2002; 40: 31-45.
8. Achten R, Verhoef G, Vanuytsel L, De Wolf-Peeters C. T-cell/histiocyte- rich large B-cell lymphoma: a distinct clinicopathologic entity. J Clin Oncol 2002; 20: 1269-77.
9. Miettinen M, Franssila KO, Saxen E. Hodgkin's disease, lymphocytic predominance nodular. Increased risk for subsequent non-Hodgkin's lymphomas. Cancer 1983; 51: 2293-300.
10. Ramuz O, Bouabdallah R, Xerri L. Lymphome B riche en T et histiocytes: variante morphologique ou entité anatomo-clinique? Hématologie 2003; 9: 191-9.
11. Chittal SM, Brousset P, Voigt JJ, Delsol G. Large B-cell lymphoma rich in T-cells and simulating Hodgkin's disease. Histopathology 1991; 19: 211-20.
12. Molina T, Diebold J. Hodgkin's nodular paragranuloma (nodular Hodgkin's disease, with lymphocytic predominance): apropos of 29 cases. Bull Cancer 1987; 74: 463-72.
13. Poppema S, Kaiserling E, Lennert K. Hodgkin's disease with lymphocytic predominance, nodular type (nodular paragranuloma) and progressively transformed germinal centres-a cytohistological study. Histopathology 1979; 3: 295-308.
14. Hansmann ML, Zwingers T, Boske A, Loffler H, Lennert K. Clinical features of nodular paragranuloma (Hodgkin's disease, lymphocyte predominance type, nodular). J Cancer Res Clin Oncol 1984; 108: 321-30.
15. Hansmann ML, Stein H, Fellbaum C, Hui PK, Parwaresch MR, Lennert K. Nodular paragranuloma can transform into high-grade malignant lymphoma of B type. Hum Pathol 1989; 20: 1169-75.
16. Sextro M, Diehl V, Franklin J, Hansmann ML, Anagnostopoulos I, Marafioti T et al. Lymphocyte predominant Hodgkin's disease-a workshop report. European Task Force on Lymphoma. Ann Oncol 1996; 7: 61-5.
17. Pellegrino B, Terrier-Lacombe MJ, Oberlin O, Leblanc T, Perel Y, Bertrand Y et al. Study of the French Society of Pediatric Oncology. Lymphocyte-predominant Hodgkin's lymphoma in children: therapeutic abstention after initial lymph node resection-a Study of the French Society of Pediatric Oncology. J Clin Oncol 2003; 21: 2948-52.
18. Bennett MH, MacLennan KA, Vaughan Hudson G, Vaughan Hudson B. Non-Hodgkin's lymphoma arising in patients treated for Hodgkin's disease in the BNLI: a 20-year experience. British National Lymphoma Investigation. Ann Oncol 1991; 2: 83-92.
19. Anagnostopoulos I, Hansmann ML, Franssila K, Harris M, Harris NL, Jaffe ES et al. European Task Force on Lymphoma project on lymphocyte predominance Hodgkin disease: histologic and immunohistologic analysis of submitted cases reveals 2 types of Hodgkin disease with a nodular growth pattern and abundant lymphocytes. Blood 2000; 96: 1889-99.
20. Rudiger T, Ott G, Ott MM, Muller-Deubert SM, Muller-Hermelink HK. Differential diagnosis between classic Hodgkin's lymphoma, T-cell-rich B-cell lymphoma, and paragranuloma by paraffin immunohistochemistry. Am J Surg Pathol 1998; 22: 1184-91.
21. Meignin V, Brière J, Brice P, Gisselbrecht C, Gaulard P, Janin A. Hodgkin disease with nodular lymphocytic predominance or type 1 (paragranuloma of Poppema-Lennert): a clinico-pathological entity. Study of 21 cases and review of the literature Ann Pathol 2000; 20: 19-24.
22. Kraus MD, Haley J. Lymphocyte predominance Hodgkin's disease: the use of bcl-6 and CD57 in diagnosis and differential diagnosis. Am J Surg Pathol 2000; 24: 1068-78.
23. Wlodarska I, Nooyen P, Maes B, Martin-Subero JI, Siebert R, Pauwels P et al. Frequent occurrence of BCL6 rearrangements in nodular lymphocyte predominance Hodgkin lymphoma but not in classical Hodgkin lymphoma. Blood 2003; 101: 706-10.
24. Chittal SM, Caveriviere P, Schwarting R, Gerdes J, Al Saati T, Rigal-Huguet F et al. Monoclonal antibodies in the diagnosis of Hodgkin's disease. The search for a rational panel. Am J Surg Pathol 1988; 12: 9-21.
25. Uherova P, Valdez R, Ross CW, Schnitzer, Finn WG. Nodular lymphocyte predominant Hodgkin lymphoma. An immunophenotypic reappraisal based on a single-institution experience. Am J Clin Pathol 2003; 119: 192-8.
26. Poppema S, Timens W, Visser L. Nodular lymphocyte predominance type of Hodgkin's disease is a B cell lymphoma. Adv Exp Med Biol 1985; 186: 963-9.
27. Kamel OW, Gelb AB, Shibuya RB, Warnke RA. Leu 7 (CD57) reactivity distinguishes nodular lymphocyte predominance Hodgkin's disease from nodular sclerosing Hodgkin's disease, T-cell-rich B-cell lymphoma and follicular lymphoma. Am J Pathol 1993; 142: 541-6.
28. Stein H, Marafioti T, Foss HD, Laumen H, Hummel M, Anagnostopoulos I et al. Down-regulation of BOB.1/OBF.1 and Oct2 in classical Hodgkin disease but not in lymphocyte predominant Hodgkin disease correlates with immunoglobulin transcription. Blood 2001; 97: 496-501.
29. Ohno T, Stribley JA, Wu G, Hinrichs SH, Weisenburger DD, Chan WC. Clonality in nodular lymphocyte-predominant Hodgkin's disease. N Engl J Med 1997; 337: 459-65.
30. Marafioti T, Hummel M, Anagnostopoulos I, Foss HD, Falini B, Delsol G et al. Origin of nodular lymphocyte-predominant Hodgkin's disease from a clonal expansion of highly mutated germinal-center B cells. N Engl J Med 1997; 337: 453-8.
31. Herbst H, Dallenbach F, Hummel M, Niedobitek G, Pileri S, Muller-Lantzsch N et al. Epstein-Barr virus latent membrane protein expression in Hodgkin and Reed-Sternberg cells. Proc Natl Acad Sci USA 1991; 88: 4766-70.
32. Shibata D, Hansmann ML, Weiss LM, Nathwani BN. Epstein-Barr virus infections and Hodgkin's disease: a study of fixed tissues using the polymerase chain reaction. Hum Pathol 1991; 22: 1262-7.
33. Lennert K. Malignant lymphomas other than Hodgkin's disease. New York: Springer-Verlag, 1978
34. Bräuninger A, Yang W, Wacker HH, Rajewsky K, Kuppers R, Hansmann ML. B-cell development in progressively transformed germinal centers: similarities and differences compared with classical germinal centers and lymphocyte-predominant Hodgkin disease. Blood 2001; 97: 714-9.
35. Osborne BM, Butler JJ, Gresik MV. Progressive transformation of germinal centers: comparison of 23 pediatric patients to the adult population. Mod Pathol 1992; 5: 135-40.
36. Diehl V, Sextro M, Franklin J, Hansmann ML, Harris N, Jaffe E et al. Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin's disease and lymphocyte-rich classical Hodgkin's disease: report from the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin's Disease. J Clin Oncol 1999; 17: 776-83.
37. Stein H, Mason DY, Gerdes J, O'Connor N, Wainscoat J, Pallesen G et al. The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood 1985; 66: 848-58.
38. Falini B, Pileri S, Stein H, Dieneman D, Dallenbach F, Delsol G et al. Variable expression of leucocyte-common (CD45) antigen in CD30 (Kil)-positive anaplastic large-cell lymphoma: implications for the differential diagnosis between lymphoid and non lymphoid malignancies. Hum Pathol 1990; 21: 624-9.
39. Falini B, Bigerna B, Pasqualucci L, Fizzotti M, Martelli MF, Pileri S et al. Distinctive expression pattern of the BCL-6 protein in nodular lymphocyte predominance Hodgkin's disease. Blood 1996; 87: 465-71.
40. Carbone A, Gloghini A, Gaidano G, Franceschi S, Capello D, Drexler HG et al. Expression status of BCL-6 and syndecan-1 identifies distinct histogenetic subtypes of Hodgkin's disease. Blood 1998; 92: 2220-8.
41. Dogan A, Bagdi E, Munson P, Isaacson PG. CD10 and BCL-6 expression in paraffin sections of normal lymphoid tissue and B-cell lymphomas. Am J Surg Pathol 2000; 24: 846-52.
42. Marafioti T, Hummel M, Foss HD, Laumen H, Korbjuhn P, Anagnostopoulos I et al. Hodgkin and reed-sternberg cells represent an expansion of a single clone originating from a germinal center B-cell with functional immunoglobulin gene rearrangements but defective immunoglobulin transcription. Blood 2000; 95: 1443-50.
43. Izban KF, Nawrocki JF, Alkan S, Hsi ED. Monoclonal IgH gene rearrangement in microdissected nodules from nodular sclerosis Hodgkin disease. Am J Clin Pathol 1998; 110: 599-606.
44. Jundt F, Kley K, Anagnostopoulos I, Schulze Probsting K, Greiner A, Mathas S et al. Loss of PU.1 expression is associated with defective immunoglobulin transcription in Hodgkin and Reed-Stemberg cells of classical Hodgkin disease. Blood 2002; 99: 3060-2.
45. Torlakovic E, Tierens A, Dang HD, Delabie J. The transcription factor PU.1, necessary for B-cell development is expressed in lymphocyte predominance, but not classical Hodgkin's disease. Am J Pathol 2001; 159: 1807-14.
46. Seitz V, Hummel M, Anagnostopoulos I, Stein H. Analysis of BCL-6 mutations in classic Hodgkin disease of the B- and T-cell type. Blood 2001; 97: 2401-5
47. Bräuninger A, Wacker H-H, Rajewsky K, Küppers R, Hansmann M-L. Typing the histogenetic origin of the tumor cells of lymphocyte-rich classical Hodgkin's lymphoma in relation to tumor cells of classical and lymphocyte-predominance Hodgkin's lymphoma. Cancer Res 2003; 63: 1644-1651.
48. Carbone A, Gloghini A, Aldinucci D, Gattei V, Dalla-Favera R, Gaidano G. Expression pattern of MUM1/IRF4 in the spectrum of pathology of Hodgkin's disease. Br J Haematol 2002; 117: 366-72.
49. Schwering I, Brauninger A, Klein U, Jungnickel B, Tinguely M, Diehl V et al. Loss of the B-lineage-specific gene expression program in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. Blood 2003; 101: 1505-12.
50. Bargou RC, Leng C, Krappmann D, Emmerich F, Mapara MY, Bommert K et al. High-level nuclear NF-kappa B and Oct-2 is a common feature of cultured Hodgkin/Reed-Sternberg cells. Blood 1996; 87: 4340-7.
51. Jungnickel B, Staratschek-Jox A, Brauninger A, Spieker T, Wolf J, Diehl V et al. Clonal deleterious mutations in the IkappaBalpha gene in the malignant cells in Hodgkin's lymphoma. J Exp Med 2000; 191: 395-402.
52. Krappmann D, Emmerich F, Kordes U, Scharschmidt E, Dorken B, Scheidereit C. Molecular mechanisms of constitutive NF-kappaB/Rel activation in Hodgkin/Reed-Sternberg cells. Oncogene 1999; 18: 943-53.
53. Niedobiteck G, Young LS, Herbst H. Epstein-Barr virus infection and the pathogenesis of malignant lymphomas. Cancer Surv 1997; 30: 143-62
54. Bouabdallah R, Mounier N, Guettier C, Molina T, Ribrag V, Thieblemont C et al. T-cell/histiocyte-rich large B-cell lymphomas and classical diffuse large B-cell lymphomas have similar outcome after chemotherapy: a matched-control analysis. J Clin Oncol 2003; 21: 1271-7.
55. Hermine O, Haioun C, Lepage E, d'Agay MF, Brière J, Lavignac C et al. Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma. Groupe d'Etude des Lymphomes de l'Adulte (GELA). Blood 1996; 87: 265-72.
56. Gascoyne RD, Adomat SA, Krajewski S, Krajewska M, Horsman DE, Tolcher AW et al. Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma. Blood 1997; 90: 244-51.
57. Delabie J, Vandenberghe E, Kennes C, Verhoef G, Foschini MP, Stul M et al. Histiocyte-rich B-cell lymphoma. A distinct clinicopathologic entity possibly related to lymphocyte predominant Hodgkin's disease, paragranuloma subtype. Am J Surg Pathol 1992; 16: 37-48.
58. Achten R, Verhoef G, Vanuytsel L, De Wolf-Peeters C. Histiocyte-rich, T-cell-rich B-cell lymphoma: a distinct diffuse large B-cell lymphoma subtype showing characteristic morphologic and immunophenotypic features. Histopathology 2002; 40: 31-45.
59. Fraga M, Sanchez-Verde L, Forteza J, Garcia-Rivero A, Piris MA. T-cell/histiocyte-rich large B-cell lymphoma is a disseminated aggressive neoplasm: differential diagnosis from Hodgkin's lymphoma. Histopathology 2002; 41: 216-29.
60. Lim MS, Beaty M, Sorbara L, Cheng RZ, Pittaluga S, Raffeld M et al. T-cell/histiocyte-rich large B-cell lymphoma: a heterogeneous entity with derivation from germinal center B cells. Am J Surg Pathol 2002; 26: 1458-66.
61. Felgar RE, Steward KR, Cousar JB, Macon WR. T-cell-rich large-B-cell lymphomas contain non-activated CD8+ cytolytic T cells, show increased tumor cell apoptosis, and have lower Bcl-2 expression than diffuse large-B-cell lymphomas. Am J Pathol 1998; 153: 1707-15.
62. Franke S, Wlodarska I, Maes B, Vandenberghe P, Achten R, Hagemeijer A et al. Comparative genomic hybridization pattern distinguishes T-cell/histiocyte- rich B-cell lymphoma from nodular lymphocyte predominance Hodgkin's lymphoma. Am J Pathol 2002; 161: 1861-7.
63. Johansson B, Mertens F, Mitelman F. Secondary chromosomal abnormalities in acute leukemias. Leukemia 1994; 8: 953-62.
64. Brauninger A, Kuppers R, Spieker T, Siebert R, Strickler JG, Schlegelberger B et al. Molecular analysis of single B cells from T-cell-rich B-cell lymphoma shows the derivation of the tumor cells from mutating germinal center B cells and exemplifies means by which immunoglobulin genes are modified in germinal center B cells. Blood 1999; 93: 2679-87.
65. Brauninger A, Hansmann ML, Strickler JG, Dummer R, Burg G, Rajewsky K et al. Identification of common germinal-center B-cell precursors in two patients with both Hodgkin's disease and non-Hodgkin's lymphoma. N Engl J Med 1999; 340: 1239-47.
66. Krenacs L, Himmelmann AW, Quintanilla-Martinez L, Fest T, Riva A, Wellmann A et al. Transcription factor B-cell-specific activator protein (BSAP) is differentially expressed in B cells and in subsets of B-cell lymphomas. Blood 1998; 92: 1308-16.
67. Foss HD, Reusch R, Demel G, Lenz G, Anagnostopoulos I, Hummel M et al. Frequent expression of the B-cell-specific activator protein in Reed-Sternberg cells of classical Hodgkin's disease provides further evidence for its B-cell origin. Blood 1999; 94: 3108-13.